Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.35 |
| ▸ | TACR3 | P29371 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095035 | 0.92 | P2RX7 (0.43) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10094990 | 0.84 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10095013 | 0.80 | P2RX7 (0.41) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10094988 | 0.80 | P2RX7 (0.43) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10095032 | 0.80 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13117218 | 0.79 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13120556 | 0.78 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2628937 | 0.78 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL15580323 | 0.78 | P2RX7 (0.44) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13281880 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | CYP3A4 44/4885CYP2C9 1097/4885CYP1A2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.